CON
Concentra Group Holdings Parent, Inc.
Medical - Equipment & Services
Market Cap$3.03B
5Y Perf.+3.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CON vs USPH
Revenue, margins, valuation, and 5-year total return — side by side.
USPH
U.S. Physical Therapy, Inc.
Medical - Care Facilities
Market Cap$897M
5Y Perf.-39.2%
CON vs USPH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CON | USPH |
|---|---|---|
| Industry | Medical - Equipment & Services | Medical - Care Facilities |
| Market Cap | $3.03B | $897M |
| Revenue (TTM) | $2.23B | $695M |
| Net Income (TTM) | $178M | $11M |
| Gross Margin | 28.7% | 22.0% |
| Operating Margin | 89.9% | 12.2% |
| Forward P/E | 16.3x | 20.9x |
| Total Debt | $2.10B | $426M |
| Cash & Equiv. | $80M | $36M |
CON vs USPH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CON
USPH
| Stock | Jul 24 | May 26 | Return |
|---|---|---|---|
| Concentra Group Hol… (CON) | 100 | 103.6 | +3.6% |
| U.S. Physical Thera… (USPH) | 100 | 60.8 | -39.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CON vs USPH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CON leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. U.S. Physical Therapy, Inc. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
CON
Concentra Group Holdings Parent, Inc.
The Defensive Pick
CON carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.69, current ratio 1.14x
- Beta 0.69, yield 1.1%, current ratio 1.14x
- Lower P/E (16.3x vs 20.9x)
Best for: sleep-well-at-night and defensive
USPH
U.S. Physical Therapy, Inc.
The Income Pick
USPH is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 5 yrs, beta 0.93, yield 3.1%
- Rev growth 16.3%, EPS growth -22.8%, 3Y rev CAGR 12.2%
- 22.6% 10Y total return vs CON's 6.7%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | USPH | 16.3% revenue growth vs CON's 13.9% |
| Value | CON | Lower P/E (16.3x vs 20.9x) |
| Quality / Margins | CON | 8.0% margin vs USPH's 1.5% |
| Stability / Safety | CON | Beta 0.69 vs USPH's 0.93 |
| Dividends | USPH | 3.1% yield, 5-year raise streak, vs CON's 1.1% |
| Momentum (1Y) | CON | +9.1% vs USPH's -14.3% |
| Efficiency (ROA) | CON | 6.1% ROA vs USPH's 0.9%, ROIC 69.4% vs 5.6% |
CON vs USPH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
CON vs USPH — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCONLAGGINGUSPH
USPHU.S. Physical Therapy…
1leads
CONConcentra Group Holdi…
3leads
6 Total Categories
CATEGORYLEADERvs USPHMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CON6/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
CON5/6
Risk & VolatilityBeta, volatility, and downside exposure
CON2/2
Analyst OutlookRatings, price targets, and dividends
USPH2/2
Income & Cash Flow (Last 12 Months)
CON leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CON is the larger business by revenue, generating $2.2B annually — 3.2x USPH's $695M. CON is the more profitable business, keeping 8.0% of every revenue dollar as net income compared to USPH's 1.5%. On growth, CON holds the edge at +13.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CONConcentra Group H… | USPHU.S. Physical The… |
|---|---|---|
| RevenueTrailing 12 months | $2.2B | $695M |
| EBITDAEarnings before interest/tax | $2.1B | $107M |
| Net IncomeAfter-tax profit | $178M | $11M |
| Free Cash FlowCash after capex | $293M | $67M |
| Gross MarginGross profit ÷ Revenue | +28.7% | +22.0% |
| Operating MarginEBIT ÷ Revenue | +89.9% | +12.2% |
| Net MarginNet income ÷ Revenue | +8.0% | +1.5% |
| FCF MarginFCF ÷ Revenue | +13.1% | +9.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +13.7% | +7.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.8% | -115.0% |
CON leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
Evenly matched — CON and USPH each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 18.2x trailing earnings, CON trades at a 56% valuation discount to USPH's 41.5x P/E. On an enterprise value basis, CON's 2.3x EV/EBITDA is more attractive than USPH's 12.5x.
| Metric | CONConcentra Group H… | USPHU.S. Physical The… |
|---|---|---|
| Market CapShares × price | $3.0B | $897M |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | 18.16x | 41.55x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.29x | 20.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 2.34x | 12.52x |
| Price / SalesMarket cap ÷ Revenue | 1.40x | 1.15x |
| Price / BookPrice ÷ Book value/share | 7.20x | 1.16x |
| Price / FCFMarket cap ÷ FCF | 15.40x | 14.71x |
Evenly matched — CON and USPH each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
Evenly matched — CON and USPH each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
CON delivers a 43.7% return on equity — every $100 of shareholder capital generates $44 in annual profit, vs $1 for USPH. USPH carries lower financial leverage with a 0.55x debt-to-equity ratio, signaling a more conservative balance sheet compared to CON's 5.00x.
| Metric | CONConcentra Group H… | USPHU.S. Physical The… |
|---|---|---|
| ROE (TTM)Return on equity | +43.7% | +1.4% |
| ROA (TTM)Return on assets | +6.1% | +0.9% |
| ROICReturn on invested capital | +69.4% | +5.6% |
| ROCEReturn on capital employed | +84.9% | +7.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 5.00x | 0.55x |
| Net DebtTotal debt minus cash | $2.0B | $390M |
| Cash & Equiv.Liquid assets | $80M | $36M |
| Total DebtShort + long-term debt | $2.1B | $426M |
| Interest CoverageEBIT ÷ Interest expense | 4.59x | 15.42x |
Evenly matched — CON and USPH each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
CON leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CON five years ago would be worth $10,669 today (with dividends reinvested), compared to $5,664 for USPH. Over the past 12 months, CON leads with a +9.1% total return vs USPH's -14.3%. The 3-year compound annual growth rate (CAGR) favors CON at 2.2% vs USPH's -17.4% — a key indicator of consistent wealth creation.
| Metric | CONConcentra Group H… | USPHU.S. Physical The… |
|---|---|---|
| YTD ReturnYear-to-date | +22.0% | -24.6% |
| 1-Year ReturnPast 12 months | +9.1% | -14.3% |
| 3-Year ReturnCumulative with dividends | +6.7% | -43.7% |
| 5-Year ReturnCumulative with dividends | +6.7% | -43.4% |
| 10-Year ReturnCumulative with dividends | +6.7% | +22.6% |
| CAGR (3Y)Annualised 3-year return | +2.2% | -17.4% |
CON leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
CON leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CON is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than USPH's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CON currently trades 95.6% from its 52-week high vs USPH's 63.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CONConcentra Group H… | USPHU.S. Physical The… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.70x | 1.00x |
| 52-Week HighHighest price in past year | $24.68 | $93.50 |
| 52-Week LowLowest price in past year | $18.55 | $58.55 |
| % of 52W HighCurrent price vs 52-week peak | +95.6% | +63.1% |
| RSI (14)Momentum oscillator 0–100 | 56.1 | 46.1 |
| Avg Volume (50D)Average daily shares traded | 654K | 171K |
CON leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
USPH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates CON as "Buy" and USPH as "Buy". Consensus price targets imply 72.9% upside for USPH (target: $102) vs 33.4% for CON (target: $32). For income investors, USPH offers the higher dividend yield at 3.06% vs CON's 1.06%.
| Metric | CONConcentra Group H… | USPHU.S. Physical The… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $31.50 | $102.00 |
| # AnalystsCovering analysts | 4 | 13 |
| Dividend YieldAnnual dividend ÷ price | +1.1% | +3.1% |
| Dividend StreakConsecutive years of raises | 0 | 5 |
| Dividend / ShareAnnual DPS | $0.25 | $1.80 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | +0.6% |
USPH leads this category, winning 2 of 2 comparable metrics.
Key Takeaway
CON leads in 3 of 6 categories (Income & Cash Flow, Total Returns). USPH leads in 1 (Analyst Outlook). 2 tied.
Best OverallConcentra Group Holdings Pa… (CON)Leads 3 of 6 categories
Loading custom metrics...
CON vs USPH: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is CON or USPH a better buy right now?
For growth investors, U.
S. Physical Therapy, Inc. (USPH) is the stronger pick with 16. 3% revenue growth year-over-year, versus 13. 9% for Concentra Group Holdings Parent, Inc. (CON). Concentra Group Holdings Parent, Inc. (CON) offers the better valuation at 18. 2x trailing P/E (16. 3x forward), making it the more compelling value choice. Analysts rate Concentra Group Holdings Parent, Inc. (CON) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CON or USPH?
On trailing P/E, Concentra Group Holdings Parent, Inc.
(CON) is the cheapest at 18. 2x versus U. S. Physical Therapy, Inc. at 41. 5x. On forward P/E, Concentra Group Holdings Parent, Inc. is actually cheaper at 16. 3x.
03Which is the better long-term investment — CON or USPH?
Over the past 5 years, Concentra Group Holdings Parent, Inc.
(CON) delivered a total return of +6. 7%, compared to -43. 4% for U. S. Physical Therapy, Inc. (USPH). Over 10 years, the gap is even starker: USPH returned +23. 1% versus CON's +9. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CON or USPH?
By beta (market sensitivity over 5 years), Concentra Group Holdings Parent, Inc.
(CON) is the lower-risk stock at 0. 70β versus U. S. Physical Therapy, Inc. 's 1. 00β — meaning USPH is approximately 44% more volatile than CON relative to the S&P 500. On balance sheet safety, U. S. Physical Therapy, Inc. (USPH) carries a lower debt/equity ratio of 55% versus 5% for Concentra Group Holdings Parent, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CON or USPH?
By revenue growth (latest reported year), U.
S. Physical Therapy, Inc. (USPH) is pulling ahead at 16. 3% versus 13. 9% for Concentra Group Holdings Parent, Inc. (CON). On earnings-per-share growth, the picture is similar: Concentra Group Holdings Parent, Inc. grew EPS 0. 0% year-over-year, compared to -22. 8% for U. S. Physical Therapy, Inc.. Over a 3-year CAGR, USPH leads at 12. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CON or USPH?
Concentra Group Holdings Parent, Inc.
(CON) is the more profitable company, earning 8. 0% net margin versus 1. 9% for U. S. Physical Therapy, Inc. — meaning it keeps 8. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CON leads at 96. 5% versus 10. 3% for USPH. At the gross margin level — before operating expenses — CON leads at 28. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CON or USPH more undervalued right now?
On forward earnings alone, Concentra Group Holdings Parent, Inc.
(CON) trades at 16. 3x forward P/E versus 20. 9x for U. S. Physical Therapy, Inc. — 4. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USPH: 72. 9% to $102. 00.
08Which pays a better dividend — CON or USPH?
All stocks in this comparison pay dividends.
U. S. Physical Therapy, Inc. (USPH) offers the highest yield at 3. 1%, versus 1. 1% for Concentra Group Holdings Parent, Inc. (CON).
09Is CON or USPH better for a retirement portfolio?
For long-horizon retirement investors, Concentra Group Holdings Parent, Inc.
(CON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 70), 1. 1% yield). Both have compounded well over 10 years (CON: +9. 1%, USPH: +23. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CON and USPH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CON is a small-cap quality compounder stock; USPH is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CON: 13.7% · USPH: 7.7%)P/E Ratio<
x
(CON: 18.2x · USPH: 41.5x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.